Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals' stock has been impacted by several key events. Agios addressed concerns from an analyst report regarding patient safety related to PYRUKYND. The FDA extended the PDUFA goal date for PYRUKYND for thalassemia, leading to a stock price drop. The CHMP adopted a positive opinion for PYRUKYND in thalassemia. The company reported its Third Quarter 2025 financial results, with PYRUKYND net revenues increasing. Agios announced topline results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease. The FDA approved AQVESME for thalassemia, leading to BofA Securities raising its price target for AGIO. Agios outlined its 2026 strategic priorities and key milestones. Agios is scheduled to host a conference call to report its fourth quarter and full year 2025 financial results and business highlights. The stock has also experienced high volatility.

The demand for Agios Pharmaceuticals' products is generally not subject to significant seasonality because they develop and commercializes therapies for rare, chronic diseases such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. These conditions require ongoing treatment, and patient needs typically remain consistent throughout the year.

Agios Pharmaceuticals, Inc., a biopharmaceutical company in Cambridge, Massachusetts, focuses on discovering and developing innovative medicines in cellular metabolism for rare diseases. Its lead product, PYRUKYND (mitapivat), is approved in the U.S. for hemolytic anemias in adults with pyruvate kinase (PK) deficiency and is in Phase 3 trials for sickle cell disease and PK deficiency in pediatric patients, as well as for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. In December 2025, the U.S. FDA approved AQVESME (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. The company's pipeline also includes tebapivat, AG-181, and AG-236.

Agios Pharmaceuticals' primary operations are centralized at its headquarters in Cambridge, Massachusetts, United States. The company manages its global research programs, clinical trials, regulatory interactions, and commercialization strategies from this central hub. Its therapies and research initiatives have a global reach, impacting patients and collaborating with researchers and healthcare providers worldwide.

Agios Pharmaceuticals emphasizes a patient-centric approach, focusing on patient needs, concerns, input, and collaboration to make a meaningful difference in patients' lives and redefine rare disease treatment. The company highlights its commitment to science and building trusted partnerships with communities. In the past year, an analyst report detailed patient safety concerns related to PYRUKYND, which Agios Pharmaceuticals addressed by affirming that the drug's benefit-risk profile had not changed and emphasizing its robust pharmacovigilance practices.

Agios Pharmaceuticals, Inc. has significant institutional ownership, with 424 institutional owners and shareholders holding a total of 68,432,819 shares. Major institutional owners include Farallon Capital Management Llc, Vanguard Group Inc, BlackRock, Inc., Bellevue Group AG, Erste Asset Management GmbH, Paradigm Biocapital Advisors LP, Wellington Management Group Llp, Commodore Capital Lp, State Street Corp, and Macquarie Group Ltd. Institutional ownership accounts for approximately 96.8% of the company, while individual ownership stands at about 0.96%.